A study was conducted to compare supplemental Zn lysine (ZnLys), Zn methionine (ZnMet), ZnSO4, and ZnO on Zn, Cu, and metallothionein (MT) concentrations in various fluids and tissues of 40 wether lambs. Supplemental Zn (360 mg/kg) was fed for 3 wk, withdrawn for 4 wk, and then resumed for another week. Mineral (Zn and Cu) concentrations were determined in serum, liver, pancreas, kidney, bone, bone marrow, hoof, and leg muscle, and only Zn was determined in skin and cornea. Metallothionein concentration was determined in liver, pancreas, and kidney. By d 49 serum Zn had increased less (P < .05) for controls than for all lambs except those fed ZnMet, and on d 55 it had increased more (P < .05) for ZnLys than for all but ZnSO4. There were no treatment effects in serum Cu concentration, but overall Cu concentration fell slightly for all treatments from d 0. The ZnLys-treated lambs had the highest (P < .05) Zn accumulation (581, 389, and 340 mg/kg) in kidney, liver, and pancreas, respectively. Both ZnSO4- and ZnMet-treated lambs had higher (P < .05) liver Zn concentrations (195 and 198 mg/kg, respectively) than the control lambs (127 mg/kg). Mean Zn concentration of bone, bone marrow, cornea, skin, hoof, and muscle was not different (P > .05) for lambs among treatments. The ZnLys-treated lambs had the highest (P < .05) MT concentrations (79, 167, and 68 micrograms MT/g for liver, kidney, and pancreas, respectively). Mean muscle Cu concentration was highest (P < .05) for controls (10 mg/kg).(ABSTRACT TRUNCATED AT 250 WORDS)
Even after radiation treatment, prostate cancer (PCa) patients receiving radiotherapy (RT) are still at risk for disease progression and recurrence. Predicting outcomes associated with cancer treatment is critical to PCa survivorship given that the 5-year survival rates for local and regional stage PCa is nearly 100%. Radiogenomics is a promising field of research focused on identifying genomic markers that can provide clinically useful prognostic predictions regarding radiation response and can potentially serve as the basis for personalized RT where cancer management is tailored to fit each individual patient. Circulating cell-free (ccfDNA) DNA has been found to 1) be associated with radiation sensitivity or toxicity, 2) relapse or recurrence, and 3) risk for the development of metastases before, during or following photon RT. Proton therapy, alternative to photon therapy, is a promising treatment that can reduce excess radiation dose and, in turn, the risk for adverse events. However, few studies have been done to determine if ccfDNA can predict response in proton radiation, which purports superior dose distribution, avoiding healthy tissues, minimizing the exit dose, and potentially reducing overall toxicity. The overall aim of this study is to determine if the quantity of ccfDNA is associated with PCa risk groups. We hypothesized that PCa patients within the highest risk group have quantitatively increased levels of ccfDNA compared to those in low and intermediate risk groups. This study leveraged the University of Florida Health Proton Therapy Institute Outcomes Tracking Protocol biobank of PCa patients with plasma and serum collected before, during and after proton RT. Isolation of ccfDNA at baseline, during treatment, and following treatment was undertaken and ccfDNA quantities were compared among patients in the low, intermediate and high risk groups using ANOVA. Our results indicate that the quantity difference between baseline and day 14 of treatment (p=0.055), 2 weeks post-treatment (p=0.54), and 4 weeks post-treatment (p=0.002) was associated with risk group. There was trend towards increasing ccfDNA quantity, as risk group increased; however, there was no correlation between risk group and treatment times using the Pearson correlation. Our results were consistent in that high ccfDNA quantity was associated with PCa risk. This is the first study determining the application of ccfDNA quantity on prostate cancer outcomes in patients undergoing proton RT. Identifying the determinants of radiation-related adverse outcomes will help inform impending predictive genomic technologies and improve cancer-related outcomes and survivorship. Citation Format: Andrew Bass, Johnny Velasquez, Moein Rajaei, Curtis Bryant, Nancy Mendenhall, Luisel J. Ricks-Santi. Association of circulating cell-free DNA and prostate cancer risk groups in patients undergoing proton therapy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5594.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.